Clinical experience with drugs targeting Bruton's Tyrosine Kinase (BTK) Book Section
| Authors: | Aronson, J.; Mato, A. R.; Coombs, C. C.; Islam, P.; Roeker, L. E.; Eyre, T. |
| Editors: | O'Connor, O. A.; Ansell, S. M.; Seymour, J. F. |
| Article/Chapter Title: | Clinical experience with drugs targeting Bruton's Tyrosine Kinase (BTK) |
| Abstract: | The introduction of inhibitors of Brutons Tyrosine Kinase (BTK) have dramatically changed the landscape of care for patients with many lymphoid malignancies, including prominently CLL, but also in mantle cell lymphoma, marginal zone lymphoma and Waldenstrom's macroglobulinemia. Successive generations of new BTK inhibitors have led to drugs with improved selectivity, and generally less toxicity. These agents have now thoroughly penetrated the front-line management of CLL, and in combination with drugs targeting Bcl-2 and PI3K appear to be dramatically improving efficacy, at least as demonstrated by the state of minimal residual disease. Future research on how to optimize the use of this class of drugs will focus on issues around time-limited administration, which will likely become more feasible in combination with other precision targeted drugs. © 2023 John Wiley & Sons, Inc. All rights reserved. |
| Keywords: | cll; ibrutinib; pirtobrutinib; acalibrutinib; brutons tyrosine kinase (btk); zanibrutinib |
| Book Title: | Precision Cancer Therapies |
| Volume: | 1 |
| ISBN: | 9781119819929 |
| Publisher: | Wiley Blackwell |
| Publication Place: | Hoboken, NJ |
| Date Published: | 2023-01-01 |
| Start Page: | 278 |
| End Page: | 286 |
| Language: | English |
| DOI: | 10.1002/9781119819950.ch20 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book Chapter: 20 -- 'Volume 1: From Concept to Practice" -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work